Literature DB >> 25612611

Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer.

Geoffrey L Rogers1, Masataka Suzuki, Irene Zolotukhin, David M Markusic, Laurence M Morel, Brendan Lee, Hildegund C J Ertl, Roland W Herzog.   

Abstract

The immune system represents a significant barrier to successful gene therapy with adeno-associated viral (AAV) vectors. In particular, adaptive immune responses to the viral capsid or the transgene product are of concern. The sensing of AAV by toll-like receptors (TLRs) TLR2 and TLR9 has been suggested to play a role in innate immunity to the virus and may also shape subsequent adaptive immune responses. Here, we investigated the functions of TLR2, TLR9 and the downstream signaling adaptor MyD88 in antibody and CD8+ T-cell responses. Antibody formation against the transgene product occurred largely independently of TLR signaling following gene transfer with AAV1 or AAV2 vectors, whereas loss of signaling through the TLR9-MyD88 pathway substantially reduced CD8+ T-cell responses. In contrast, MyD88 (but neither of the TLRs) regulated antibody responses to capsid. B cell-intrinsic MyD88 was required for the formation of anti-capsid IgG2c independently of vector serotype or route of administration. However, MyD88(-/-) mice instead produced anti-capsid IgG1 that emerged with delayed kinetics but nonetheless completely prevented in vivo readministration. We conclude that there are distinct roles for TLR9 and MyD88 in promoting adaptive immune responses to AAV-mediated gene transfer and that there are redundant MyD88-dependent and MyD88-independent mechanisms that stimulate neutralizing antibody formation against AAV.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25612611      PMCID: PMC4417066          DOI: 10.1159/000369273

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  41 in total

1.  Muscle as a target for supplementary factor IX gene transfer.

Authors:  Brad E Hoffman; Eric Dobrzynski; Lixin Wang; Lauren Hirao; Federico Mingozzi; Ou Cao; Roland W Herzog
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

2.  Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.

Authors:  J H McIntosh; M Cochrane; S Cobbold; H Waldmann; S A Nathwani; A M Davidoff; A C Nathwani
Journal:  Gene Ther       Date:  2011-06-30       Impact factor: 5.250

3.  Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors.

Authors:  Marianna Hösel; Mathias Broxtermann; Hanna Janicki; Knud Esser; Silke Arzberger; Pia Hartmann; Sonja Gillen; Jörg Kleeff; Dirk Stabenow; Margarete Odenthal; Percy Knolle; Michael Hallek; Ulrike Protzer; Hildegard Büning
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

4.  Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.

Authors:  Xiaomei Wang; Babak Moghimi; Irene Zolotukhin; Laurence M Morel; Ou Cao; Roland W Herzog
Journal:  Mol Ther       Date:  2014-03-10       Impact factor: 11.454

5.  Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

Authors:  L Wang; O Cao; B Swalm; E Dobrzynski; F Mingozzi; R W Herzog
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

6.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.

Authors:  Roland W Herzog; Paul A Fields; Valder R Arruda; Jeff O Brubaker; Elina Armstrong; Darryl McClintock; Dwight A Bellinger; Linda B Couto; Timothy C Nichols; Katherine A High
Journal:  Hum Gene Ther       Date:  2002-07-20       Impact factor: 5.695

8.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

Review 9.  Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.

Authors:  Elisa Masat; Giulia Pavani; Federico Mingozzi
Journal:  Discov Med       Date:  2013-06       Impact factor: 2.970

10.  Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.

Authors:  David M Markusic; Brad E Hoffman; George Q Perrin; Sushrusha Nayak; Xiaomei Wang; Paul A LoDuca; Katherine A High; Roland W Herzog
Journal:  EMBO Mol Med       Date:  2013-09-16       Impact factor: 12.137

View more
  29 in total

1.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.

Authors:  Koen Vercauteren; Brad E Hoffman; Irene Zolotukhin; Geoffrey D Keeler; Jing W Xiao; Etiena Basner-Tschakarjan; Katherine A High; Hildegund Cj Ertl; Charles M Rice; Arun Srivastava; Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2016-03-29       Impact factor: 11.454

3.  Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells.

Authors:  Geoffrey L Rogers; Jamie L Shirley; Irene Zolotukhin; Sandeep R P Kumar; Alexandra Sherman; George Q Perrin; Brad E Hoffman; Arun Srivastava; Etiena Basner-Tschakarjan; Mark A Wallet; Cox Terhorst; Moanaro Biswas; Roland W Herzog
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

4.  TLR9/MyD88/TRIF signaling activates host immune inhibitory CD200 in Leishmania infection.

Authors:  Ismael P Sauter; Katerine G Madrid; Josiane B de Assis; Anderson Sá-Nunes; Ana C Torrecilhas; Daniela I Staquicini; Renata Pasqualini; Wadih Arap; Mauro Cortez
Journal:  JCI Insight       Date:  2019-05-16

5.  Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells.

Authors:  Jamie L Shirley; Geoffrey D Keeler; Alexandra Sherman; Irene Zolotukhin; David M Markusic; Brad E Hoffman; Laurence M Morel; Mark A Wallet; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2019-11-15       Impact factor: 11.454

6.  Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.

Authors:  Roland W Herzog; Mario Cooper; George Q Perrin; Moanaro Biswas; Ashley T Martino; Laurence Morel; Cox Terhorst; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-08-01       Impact factor: 4.868

Review 7.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

8.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

Review 9.  Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.

Authors:  Natalie F Nidetz; Michael C McGee; Longping V Tse; Chengwen Li; Le Cong; Yunxing Li; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

10.  The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer.

Authors:  ZhiQuan Xiang; Raj K Kurupati; Yan Li; Klaudia Kuranda; Xiangyang Zhou; Federico Mingozzi; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2019-11-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.